PHARMA NORD ApS: Financial statements 2022
CVR: 67303016
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 439,437,000 and a net result of DKK 35,289,000 compared with DKK 57,966,000 the year before. That is a decrease of 6.5% compared with the year before. The profit margin was 8%. Equity in the 2022 report amounted to DKK 183,029,000. The solvency ratio was 40.9%. The company had 425 employees in the financial year.
- Revenue
- DKK 439,437,000
- Gross Profit
- DKK 187,535,000
- Profit/Loss
- DKK 35,289,000
- Equity
- DKK 183,029,000
- Total Assets
- DKK 447,011,000
- Employees
- 425
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 439.4 mio. | 187.5 mio. | 35.3 mio. | 183 mio. | 425 |
| 2021 | 470.2 mio. | 221 mio. | 58 mio. | 199.3 mio. | 420 |
| 2020 | 417.2 mio. | 197.9 mio. | 51.9 mio. | 170.4 mio. | 394 |
| 2019 | 333 mio. | 126.1 mio. | 41.5 mio. | 269.7 mio. | 375 |
| 2018 | 334 mio. | 132.3 mio. | 37.7 mio. | 212.7 mio. | 364 |
Official annual report
Keep an eye on PHARMA NORD ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
PHARMA NORD ApS has published its annual report for 2021. Revenue came to DKK 470,180,000, and the net result was DKK 57,966,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.